This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Unni, E. Articles by Marcelli, M. Search for Related Content PubMed PubMed Citation Articles by Unni, E. Articles by Marcelli, M.

Changes in Androgen Receptor Nongenotropic Signaling Correlate with Transition of LNCaP Cells to Androgen Independence

Departments of ¹ Medicine and ² Molecular and Cellular Biology, ³ Baylor College of Medicine and VA Medical Center, Houston, Texas; ⁴ Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas; and ⁵ Department of Cell Biology, Women’s Health Research Institute, Wyeth Pharmaceuticals, Collegeville, Pennsylvania

A cure for prostate cancer (CaP) will be possible only after a complete understanding of the mechanisms causing this disease to progress from androgen dependence to androgen independence. To carry on a careful characterization of the phenotypes of CaP cell lines before and after acquisition of androgen independence, we used two human CaP LNCaP sublines: LNCaP_nan, which is androgen dependent (AD), and LNCaP-HP, which is androgen independent (AI). In AD LNCaP_nan cells, dihydrotestosterone (DHT) stimulated in an androgen receptor (AR)-dependent way a phosphorylation signaling pathway involving steroid receptor coactivator (Src)–mitogen-activated protein/extracellular signal-regulated kinase (ERK) kinase (MEK)-1/2–ERK-1/2–cAMP-response element binding-protein (CREB). Activation of this pathway was associated with increased [³H]thymidine incorporation and resistance to apoptosis. Use of dominant-negative forms of MEK-1/2 and CREB demonstrated in LNCaP_nan cells that DHT induced [³H]thymidiine incorporation through a thus far unidentified molecule activated downstream of MEK-1/2, and antiapoptosis through phosphorylation of the transcription factor CREB. In contrast, in AI LNCaP-HP cells, the Src–MEK-1/2–ERK-1/2–CREB pathway was constitutively active. Because it was not further stimulated by addition of DHT, no increase of [³H]thymidine incorporation or apoptosis resistance was demonstrated in LNCaP-HP cells. Additional experiments showed that Src and the scaffold protein MNAR coimmunoprecipitated with AR, indicating a role for Src as an apical molecule in the Src–MEK-1/2–ERK-1/2–CREB pathway. Interestingly, differences between the two cell lines were that in LNCaP-HP cells presence of an AI phenotype and lack of response to DHT were associated with constitutive activation of the protein kinase Src and interaction among Src, AR, and MNAR. In contrast, in LNCaP_nan cells, presence of an AD phenotype and ability to respond to DHT were associated with DHT-dependent activation of Src kinase activity and interaction among Src, AR, and MNAR. Intriguingly, in LNCaP_nan cells, we found that transcription through the prototypical CREB-responsive promoter c-fos could be induced in a DHT-dependent way, and this action was inhibited by the AR antagonist Casodex and MEK-1 inhibitor PD98059. In contrast, transcription through the PSA P/E promoter, a prototypical AR-dependent promoter directly activated by agonist, was obliterated only by Casodex. Additional experiments with genital skin fibroblasts derived from patients with a variety of AR abnormalities indicated that nongenotropic AR signaling does not depend on an intact DNA-binding domain or on the ability of AR to translocate to the nucleus. The results suggest the following: (1) Constitutive activation of the Src–MEK-1/2–ERK-1/2–CREB pathway is associated with the AI phenotype observed in LNCaP-HP cells. (2) Activation of the Src–MEK-1/2–ERK-1/2–CREB pathway is DHT dependent in AD LNCaP_nan cells. (3) DHT activation of this pathway is associated with induction of [³H]thymidine incorporation by a molecule activated downstream of MEK-1/2 and of antiapoptosis through activation of the transcription factor CREB in AD LNCaP_nan cells. (4) AR regulates transcription either directly upon ligand binding and nuclear translocation or indirectly through kinase pathways leading to activation of downstream transcription factors. (5) Nuclear translocation and ability of the DNA-binding domain of AR to interact with DNA are not prerequisites for nongenotropic AR activity.

This article has been cited by other articles:

				M. Genua, G. Pandini, D. Sisci, G. Castoria, M. Maggiolini, R. Vigneri, and A. Belfiore Role of Cyclic AMP Response Element-Binding Protein in Insulin-like Growth Factor-I Receptor Up-regulation by Sex Steroids in Prostate Cancer Cells Cancer Res., September 15, 2009; 69(18): 7270 - 7277. [Abstract] [Full Text] [PDF]

				S. M. Alam, M. Rajendran, S. Ouyang, S. Veeramani, L. Zhang, and M.-F. Lin A novel role of Shc adaptor proteins in steroid hormone-regulated cancers Endocr. Relat. Cancer, March 1, 2009; 16(1): 1 - 16. [Abstract] [Full Text] [PDF]

				X. Deng, H. Liu, J. Huang, L. Cheng, E. T. Keller, S. J. Parsons, and C.-D. Hu Ionizing Radiation Induces Prostate Cancer Neuroendocrine Differentiation through Interplay of CREB and ATF2: Implications for Disease Progression Cancer Res., December 1, 2008; 68(23): 9663 - 9670. [Abstract] [Full Text] [PDF]

				E. R. Levin Rapid signaling by steroid receptors Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2008; 295(5): R1425 - R1430. [Abstract] [Full Text] [PDF]

				S. Shah, J. K. Hess-Wilson, S. Webb, H. Daly, S. Godoy-Tundidor, J. Kim, J. Boldison, Y. Daaka, and K. E. Knudsen 2,2-Bis(4-Chlorophenyl)-1,1-Dichloroethylene Stimulates Androgen Independence in Prostate Cancer Cells through Combinatorial Activation of Mutant Androgen Receptor and Mitogen-Activated Protein Kinase Pathways Mol. Cancer Res., September 1, 2008; 6(9): 1507 - 1520. [Abstract] [Full Text] [PDF]

				G. Bagchi, J. Wu, J. French, J. Kim, N. H. Moniri, and Y. Daaka Androgens Transduce the G{alpha}s-Mediated Activation of Protein Kinase A in Prostate Cells Cancer Res., May 1, 2008; 68(9): 3225 - 3231. [Abstract] [Full Text] [PDF]

				K. Iguchi, M. Ito, S. Usui, A. Mizokami, M. Namiki, and K. Hirano Downregulation of Thymosin {beta}4 Expression by Androgen in Prostate Cancer LNCaP Cells J Androl, March 1, 2008; 29(2): 207 - 212. [Abstract] [Full Text] [PDF]

				S. Aggarwal, S.-W. Kim, S.-H. Ryu, W.-C. Chung, and J. S. Koo Growth Suppression of Lung Cancer Cells by Targeting Cyclic AMP Response Element-Binding Protein Cancer Res., February 15, 2008; 68(4): 981 - 988. [Abstract] [Full Text] [PDF]

				S. R. Hammes and E. R. Levin Extranuclear Steroid Receptors: Nature and Actions Endocr. Rev., December 1, 2007; 28(7): 726 - 741. [Abstract] [Full Text] [PDF]

				K. Fizazi The role of Src in prostate cancer Ann. Onc., November 1, 2007; 18(11): 1765 - 1773. [Abstract] [Full Text] [PDF]

				B. Cinar, N. K. Mukhopadhyay, G. Meng, and M. R. Freeman Phosphoinositide 3-Kinase-independent Non-genomic Signals Transit from the Androgen Receptor to Akt1 in Membrane Raft Microdomains J. Biol. Chem., October 5, 2007; 282(40): 29584 - 29593. [Abstract] [Full Text] [PDF]

				C. Festuccia, G. L. Gravina, P. Muzi, R. Pomante, L. Ventura, R. L Vessella, C. Vicentini, and M. Bologna Bicalutamide increases phospho-Akt levels through Her2 in patients with prostate cancer Endocr. Relat. Cancer, September 1, 2007; 14(3): 601 - 611. [Abstract] [Full Text] [PDF]

				A. Pedram, M. Razandi, R. C. A. Sainson, J. K. Kim, C. C. Hughes, and E. R. Levin A Conserved Mechanism for Steroid Receptor Translocation to the Plasma Membrane J. Biol. Chem., August 3, 2007; 282(31): 22278 - 22288. [Abstract] [Full Text] [PDF]

				R. Vijayvargia, M. S. May, and J. D. Fondell A Coregulatory Role for the Mediator Complex in Prostate Cancer Cell Proliferation and Gene Expression Cancer Res., May 1, 2007; 67(9): 4034 - 4041. [Abstract] [Full Text] [PDF]

				J. Cheng, S. C. Watkins, and W. H. Walker Testosterone Activates Mitogen-Activated Protein Kinase via Src Kinase and the Epidermal Growth Factor Receptor in Sertoli Cells Endocrinology, May 1, 2007; 148(5): 2066 - 2074. [Abstract] [Full Text] [PDF]

				U. Simanainen, C. M. Allan, P. Lim, S. McPherson, M. Jimenez, J. D. Zajac, R. A. Davey, and D. J. Handelsman Disruption of Prostate Epithelial Androgen Receptor Impedes Prostate Lobe-Specific Growth and Function Endocrinology, May 1, 2007; 148(5): 2264 - 2272. [Abstract] [Full Text] [PDF]

				A. P. Kumar, S. Bhaskaran, M. Ganapathy, K. Crosby, M. D. Davis, P. Kochunov, J. Schoolfield, I-T. Yeh, D. A. Troyer, and R. Ghosh Akt/cAMP-Responsive Element Binding Protein/Cyclin D1 Network: A Novel Target for Prostate Cancer Inhibition in Transgenic Adenocarcinoma of Mouse Prostate Model Mediated by Nexrutine, a Phellodendron Amurense Bark Extract Clin. Cancer Res., May 1, 2007; 13(9): 2784 - 2794. [Abstract] [Full Text] [PDF]

				J. G. Greger, N. Fursov, N. Cooch, S. McLarney, L. P. Freedman, D. P. Edwards, and B. J. Cheskis Phosphorylation of MNAR Promotes Estrogen Activation of Phosphatidylinositol 3-Kinase Mol. Cell. Biol., March 1, 2007; 27(5): 1904 - 1913. [Abstract] [Full Text] [PDF]

				S. S. Nair, Z. Guo, J. M. Mueller, S. Koochekpour, Y. Qiu, R. R. Tekmal, R. Schule, H.-J. Kung, R. Kumar, and R. K. Vadlamudi Proline-, Glutamic Acid-, and Leucine-Rich Protein-1/Modulator of Nongenomic Activity of Estrogen Receptor Enhances Androgen Receptor Functions through LIM-Only Coactivator, Four-and-a-Half LIM-Only Protein 2 Mol. Endocrinol., March 1, 2007; 21(3): 613 - 624. [Abstract] [Full Text] [PDF]

				T. Inoue, T. Yoshida, Y. Shimizu, T. Kobayashi, T. Yamasaki, Y. Toda, T. Segawa, T. Kamoto, E. Nakamura, and O. Ogawa Requirement of Androgen-Dependent Activation of Protein Kinase C{zeta} for Androgen-Dependent Cell Proliferation in LNCaP Cells and Its Roles in Transition to Androgen-Independent Cells Mol. Endocrinol., December 1, 2006; 20(12): 3053 - 3069. [Abstract] [Full Text] [PDF]

				P Singh, A Uzgare, I Litvinov, S R Denmeade, and J T Isaacs Combinatorial androgen receptor targeted therapy for prostate cancer. Endocr. Relat. Cancer, September 1, 2006; 13(3): 653 - 666. [Abstract] [Full Text] [PDF]

				A. E. Gururaj, S. K. Rayala, R. K. Vadlamudi, and R. Kumar Novel Mechanisms of Resistance to Endocrine Therapy: Genomic and Nongenomic Considerations Clin. Cancer Res., February 1, 2006; 12(3): 1001s - 1007s. [Abstract] [Full Text] [PDF]

				S. Veeramani, T.-C. Yuan, S.-J. Chen, F.-F. Lin, J. E Petersen, S. Shaheduzzaman, S. Srivastava, R. G MacDonald, and M.-F. Lin Cellular prostatic acid phosphatase: a protein tyrosine phosphatase involved in androgen-independent proliferation of prostate cancer Endocr. Relat. Cancer, December 1, 2005; 12(4): 805 - 822. [Abstract] [Full Text] [PDF]

				L. Jia and G. A. Coetzee Androgen Receptor-Dependent PSA Expression in Androgen-Independent Prostate Cancer Cells Does Not Involve Androgen Receptor Occupancy of the PSA Locus Cancer Res., September 1, 2005; 65(17): 8003 - 8008. [Abstract] [Full Text] [PDF]

				D. Haas, S. N. White, L. B. Lutz, M. Rasar, and S. R. Hammes The Modulator of Nongenomic Actions of the Estrogen Receptor (MNAR) Regulates Transcription-Independent Androgen Receptor-Mediated Signaling: Evidence that MNAR Participates in G Protein-Regulated Meiosis in Xenopus laevis Oocytes Mol. Endocrinol., August 1, 2005; 19(8): 2035 - 2046. [Abstract] [Full Text] [PDF]

				W. H Walker and J. Cheng FSH and testosterone signaling in Sertoli cells Reproduction, July 1, 2005; 130(1): 15 - 28. [Abstract] [Full Text] [PDF]

				T.-L. Cha, L. Qiu, C.-T. Chen, Y. Wen, and M.-C. Hung Emodin Down-Regulates Androgen Receptor and Inhibits Prostate Cancer Cell Growth Cancer Res., March 15, 2005; 65(6): 2287 - 2295. [Abstract] [Full Text] [PDF]

				G. Pandini, R. Mineo, F. Frasca, C. T. Roberts Jr., M. Marcelli, R. Vigneri, and A. Belfiore Androgens Up-regulate the Insulin-like Growth Factor-I Receptor in Prostate Cancer Cells Cancer Res., March 1, 2005; 65(5): 1849 - 1857. [Abstract] [Full Text] [PDF]